# Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)

> **NCT03201185** · PHASE4 · UNKNOWN · sponsor: **Hospital Clínico Universitario de Valladolid** · enrollment: 194 (actual)

## Conditions studied

- Transcatheter Aortic Valve Replacemen
- Angiotensin-Converting Enzyme Inhibitors

## Interventions

- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT03201185
- **Lead sponsor:** Hospital Clínico Universitario de Valladolid
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-10
- **Primary completion:** 2021-08-13
- **Final completion:** 2023-08
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2021-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201185, "Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03201185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*